centene corp. - CNC
CNC
Close Chg Chg %
29.11 -1.16 -3.99%
Closed Market
27.95
-1.16 (3.99%)
Volume: 22.65M
Last Updated:
Jul 18, 2025, 3:59 PM EDT
Company Overview: centene corp. - CNC
CNC Key Data
| Open $29.01 | Day Range 27.88 - 29.13 |
| 52 Week Range 27.88 - 80.59 | Market Cap $14.50B |
| Shares Outstanding 497.60M | Public Float 491.78M |
| Beta 0.44 | Rev. Per Employee N/A |
| P/E Ratio 4.34 | EPS $6.74 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 17.77M |
CNC Performance
| 1 Week | -11.10% | ||
| 1 Month | -48.62% | ||
| 3 Months | -53.95% | ||
| 1 Year | -57.80% | ||
| 5 Years | -57.82% |
CNC Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
23
Full Ratings ➔
An error occurred while fetching the data.
An error occurred while fetching the data.
Snapshot
| Average Recommendation | OVERWEIGHT | Average Target Price | 52.125 | |
| Number of Ratings | 23 | Current Quarters Estimate | 0.27 | |
| FY Report Date | 09 / 2025 | Current Year's Estimate | 3.075 | |
| Last Quarter’s Earnings | 0.245 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | 7.17 | Next Fiscal Year Estimate | 4.987 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 12 | 11 | 14 | 13 |
| Mean Estimate | 0.27 | -0.55 | 3.08 | 4.99 |
| High Estimates | 0.80 | 0.13 | 4.50 | 7.27 |
| Low Estimate | -0.17 | -1.28 | 2.20 | 3.75 |
| Coefficient of Variance | 104.05 | -80.27 | 23.28 | 20.68 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 8 | 9 | 9 |
| OVERWEIGHT | 1 | 2 | 4 |
| HOLD | 13 | 10 | 8 |
| UNDERWEIGHT | 1 | 1 | 1 |
| SELL | 0 | 0 | 0 |
| MEAN | Overweight | Overweight | Overweight |
SEC Filings for Centene Corp. - CNC
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Centene Corp. - CNC
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Mar 21, 2025 | Sarah McGinty London Chief Executive Officer; Director | 826,045 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 21, 2025 | Susan Smith Chief Operating Officer | 119,923 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 21, 2025 | Susan Smith Chief Operating Officer | 59,775 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $58.19 per share | 3,478,307.25 |
| Mar 21, 2025 | Tanya M. McNally Chief People Officer | 60,458 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 21, 2025 | Tanya M. McNally Chief People Officer | 27,377 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $58.19 per share | 1,593,067.63 |
| Mar 21, 2025 | Katie N. Casso Corporate Controller & CAO | 98,412 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 21, 2025 | Katie N. Casso Corporate Controller & CAO | 70,916 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $58.19 per share | 4,126,602.04 |
| Mar 21, 2025 | Christopher A. Koster Secretary & General Counsel | 261,707 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 21, 2025 | Christopher A. Koster Secretary & General Counsel | 175,782 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $58.19 per share | 10,228,754.58 |
| Mar 21, 2025 | Sarah McGinty London Chief Executive Officer; Director | 564,832 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $58.19 per share | 32,867,574.08 |
| Mar 21, 2025 | Andrew Lynn Asher Chief Financial Officer | 668,208 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 21, 2025 | Andrew Lynn Asher Chief Financial Officer | 444,802 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $58.19 per share | 25,883,028.38 |
| Jan 6, 2025 | Christopher J. Coughlin Director | 6,801 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jan 6, 2025 | Theodore Rapp Samuels Director | 14,037 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jan 6, 2025 | Kenneth A. Burdick Director | 362,418 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jan 6, 2025 | Wayne S. DeVeydt Director | 14,801 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jan 6, 2025 | Frederick H. Eppinger Director | 352,199 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
Centene Corp. in the News
Centene cancels in-person investor day after UnitedHealthcare CEO killing, will hold event virtually
Managed health care company Centene announced that it canceled its in-person investor day and moved to a webinar format following the killing of UnitedHealthcare CEO Brian Thompson.
Companies thought they had a plan for fall, now they are scrapping it
The swift, startling resurgence of Covid-19 cases and hospitalizations across the U.S. is causing corporate leaders to rip up playbooks for the next few months.